Related Experiment Videos
[Intrathecal methotrexate--overdosing in pediatric lymphoblastic leukemia]
H Reddemann1, G Schwesinger, L Riethdorf
1Hämatologisch-Onkologische Abteilung der Klinik für Kindermedizin, Ernst-Moritz-Arndt-Universität Greifswald.
Psychiatrie, Neurologie, Und Medizinische Psychologie
|June 1, 1987
Abstract:
Intrathecal methotrexate-overdosage in the meningosis therapy leads to CNS damages dependent on dose. It was given a own case report and a literature review with clinical symptoms and the therapy in this complication. Neuropathologic findings included demyelinisation und necrosis of the white matter.
Insights
High-dose intrathecal methotrexate for meningosis can cause central nervous system (CNS) damage. This review details clinical symptoms, treatment, and neuropathologic findings like demyelination and necrosis.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Meningosis therapy often involves intrathecal methotrexate.
- Methotrexate overdose can lead to severe neurological complications.
Observation:
- A case report and literature review were conducted.
- Clinical symptoms and therapeutic strategies for CNS complications were examined.
Findings:
- Intrathecal methotrexate overdosage is dose-dependent.
- Neuropathologic findings include demyelination and white matter necrosis.
Implications:
- Understanding these risks is crucial for safe meningosis treatment.
- Further research may optimize methotrexate dosing to prevent CNS toxicity.